![]() ![]() While only a handful clinical trials were conducted before 2012 for both radionuclides (gallium-68, 12 trials between 19 lutetium-177, 16 trials between 19) both have increasingly found application in clinical routine reflected in the rapidly increasing amount of enrolled phase 1–3 studies.Īlthough, gallium-68 was already proposed for medical use by Gleason its way to clinical application was not possible without the advancement of the primary generator design. Even more trials are enrolled for its diagnostic counterpart gallium-68 (keyword: gallium-68 268 trials ). prostate cancer (PC)), lutetium-177 is of interest, reflected in numerous clinical trials registered at (keyword: lutetium-177 87 trials ). However, not only for NETs, but also for other types of cancer (e.g. Based on the data received, the U.S. Food and Drug Administration (FDA) recently approved 177Lu-labeled DOTA-TATE for PRRT treatment. This approach allows the targeted treatment of inoperable or metastatic NETs already proven in multiple clinical trials employing radiolabeled somatostatin analogs. This concept is well established for treatment of neuroendocrine tumors (NETs) using peptide receptor radionuclide therapy (PRRT). Combining both, gallium-68 and lutetium-177, enables diagnostic molecular imaging followed by personalized treatment based on the diagnostic scan. ![]() Facilitated is this development by increasing interest in the application of its “theranostic twin” lutetium-177. In recent years, 68Ga-radiopharmaceuticals gained more and more attention due to their steadily growing clinical application. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |